Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology

Jeong, Woo Kyoung; Kang, Hyo-Jin; Choi, Sang Hyun; Park, Mi‐Suk; Yu, Mi Hye; Kim, Bohyun; You, Myung‐Won; Lim, Sanghyeok; Cho, Young Seo; Lee, Min Woo; Hwang, Jeong Ah; Lee, Jae Young; Kim, Jung Hoon; Joo, Ijin; Bae, Jae Seok; Kim, So Yeon; Chung, Yong Eun; Kim, Dong Hwan; Lee, Jeong Min

doi:10.3348/kjr.2023.0324

Cited by 10 publications

(12 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 36 In contrast, the majority (69.2%) of well-differentiated HCCs had an isoechoic pattern, which was consistent with the histology of the HCC category. 36 …”

Section: Application Of Ultrasound Technologies In Different Stages O...supporting

confidence: 68%

Ultrasonography of Hepatocellular Carcinoma: From Diagnosis to Prognosis

Hu,

Zhao,

et al. 2024

J Clin Transl Hepatol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a prominent contributor to cancer-related mortality worldwide. Early detection and diagnosis of liver cancer can significantly improve its prognosis and patient survival. Ultrasound technology, serving has undergone substantial advances as the primary method of HCC surveillance and has broadened its scope in recent years for effective management of HCC. This article is a comprehensive overview of ultrasound technology in the treatment of HCC, encompassing early detection, diagnosis, staging, treatment evaluation, and prognostic assessment. In addition, the authors summarized the application of contrast-enhanced ultrasound in the diagnosis of HCC and assessment of prognosis. Finally, the authors discussed further directions in this field by emphasizing overcoming existing obstacles and integrating cutting-edge technologies.

show abstract

“… 36 In contrast, the majority (69.2%) of well-differentiated HCCs had an isoechoic pattern, which was consistent with the histology of the HCC category. 36 …”

Section: Application Of Ultrasound Technologies In Different Stages O...supporting

confidence: 68%

Ultrasonography of Hepatocellular Carcinoma: From Diagnosis to Prognosis

Hu,

Zhao,

et al. 2024

J Clin Transl Hepatol

View full text Add to dashboard Cite

show abstract

“…1 ). 5 The arterial phase begins when microbubbles are visualized in the hepatic artery, and typically lasts for 20-35 seconds. Following the arterial phase, the portal venous phase immediately begins and continues for 2 minutes after injection.…”

Section: How To Perform Sonazoid Ceusmentioning

confidence: 99%

“…Recently, contrast-enhanced ultrasound (CEUS) with perfluorobutane (Sonazoid TM ; GE Healthcare, Milwaukee, WI, USA) has emerged as a promising tool for HCC diagnosis. 5 Perfluorobutane microbubbles have unique properties, allowing them to be selectively engulfed by intrasinusoidal macrophages (Kupffer cells); this leads to sustained enhancement of the hepatic parenchyma during CEUS examinations, 6 , 7 and Kupffer phase washout of hepatic malignancies, thereby indicating the defect by enhancing the surrounding parenchyma. 8 - 10 Additionally, this enables the real-time visualization of arterial phase hyperenhancement (APHE), which other imaging modalities cannot achieve.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis of hepatocellular carcinoma using Sonazoid: a comprehensive review

Jeong

2023

JLC

Self Cite

View full text Add to dashboard Cite

Sonazoid contrast-enhanced ultrasonography (CEUS) is a promising technique for the detection and diagnosis of focal liver lesions, particularly hepatocellular carcinoma (HCC). Recently, a collaborative effort between the Korean Society of Radiology and Korean Society of Abdominal Radiology resulted in the publication of guidelines for diagnosing HCC using Sonazoid CEUS. These guidelines propose specific criteria for identifying HCC based on the imaging characteristics observed during Sonazoid CEUS. The suggested diagnostic criteria include nonrim arterial phase hyperenhancement, and the presence of late and mild washout, or Kupffer phase washout under the premise that the early or marked washout should not occur during the portal venous phase. These criteria aim to improve the accuracy of HCC diagnosis using Sonazoid CEUS. This review offers a comprehensive overview of Sonazoid CEUS in the context of HCC diagnosis. It covers the fundamental principles of Sonazoid CEUS and its clinical applications, and introduces the recently published guidelines. By providing a summary of this emerging technique, this review contributes to a better understanding of the potential role of Sonazoid CEUS for diagnosing HCC.

show abstract

“…However, 1-2 minutes post-injection, the liver enhancement pattern may be similar but not identical to that of SVUS, since Kupffer cell uptake begins approximately 1 minute after administration [ 15 , 19 ]. As a result, the enhancement observed after the portal venous phase may represent a combination of the vascular and Kupffer phases (transitional phase or vasculo-Kupffer phase) [ 19 , 20 ]. The pure Kupffer phase (also known as the post-vascular phase) starts at approximately 10 minutes post-injection, when the microbubbles have been eliminated from the blood pool, and lasts up to 2 hours ( Fig.…”

Section: Imaging Acquisition Techniquementioning

confidence: 99%

Sonazoid-enhanced ultrasonography for noninvasive imaging diagnosis of hepatocellular carcinoma: special emphasis on the 2022 KLCA-NCC guideline

Kang¹,

Lee²,

Kim³

2023

Ultrasonography

Self Cite

View full text Add to dashboard Cite

Contrast-enhanced ultrasonography (CEUS) is a noninvasive imaging modality used to diagnose hepatocellular carcinoma (HCC) based on specific imaging features, without the need for pathologic confirmation. Two types of ultrasound contrast agents are commercially available: pure intravascular agents (such as SonoVue) and Kupffer agents (such as Sonazoid). Major guidelines recognize CEUS as a reliable imaging method for HCC diagnosis, although they differ depending on the contrast agents used. The Korean Liver Cancer Association–National Cancer Center guideline includes CEUS with either SonoVue or Sonazoid as a second-line diagnostic technique. However, Sonazoid-enhanced ultrasound is associated with several unresolved issues. This review provides a comparative overview of these contrast agents regarding pharmacokinetic features, examination protocols, diagnostic criteria for HCC, and potential applications in the HCC diagnostic algorithm.

show abstract

Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology

Cited by 10 publications

References 90 publications

Ultrasonography of Hepatocellular Carcinoma: From Diagnosis to Prognosis

Ultrasonography of Hepatocellular Carcinoma: From Diagnosis to Prognosis

Diagnosis of hepatocellular carcinoma using Sonazoid: a comprehensive review

Sonazoid-enhanced ultrasonography for noninvasive imaging diagnosis of hepatocellular carcinoma: special emphasis on the 2022 KLCA-NCC guideline

Contact Info

Product

Resources

About